Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF6002 ± Nivolumab in Advanced Solid Tumors
2023-510511-19-00Phase 2Completed
- Sponsor
- Dragonfly Therapeutics
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of DF6002 in melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 14 more (2 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Dose-limiting toxicities during first 3 weeks (Phase 1/1b) and Confirmed objective response rate by IERC (Phase 2). Started Mar 2024; status: completed.
02
Drugs
DF6002
03
Conditions
melanomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)head and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-510511-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510511-19-00.